Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero

Gene Therapy volume 12, pages 39–47 (2005)Cite this article

Abstract

In utero gene delivery could offer the advantage of treatment at an early stage for genetic disorders such as Duchenne muscular dystrophy (DMD) in which the inevitable process of muscle degeneration is already initiated at birth. Furthermore, treatment of fetal muscle with adenoviral (Ad) vectors is attractive because of a high density of Ad receptors, easy vector accessibility due to immaturity of the basal lamina and the possibility of treating stem cells. Previously, we demonstrated the efficient transduction of fetal muscle by high-capacity Ad (HC-Ad) vectors. In this study, we compared HC-Ad and first-generation Ad (FG-Ad) vectors for longevity of lacZ transgene expression, toxicity and induction of immunity after direct vector-mediated in utero gene delivery to fetal C57BL/6 mice muscle 16 days after conception (E-16). The total amount of β-galactosidase (βgal) expressed from the HC-Ad vector remained stable for the 5 months of the study, although the concentration of βgal decreased due to muscle growth. Higher survival rates that reflect lower levels of toxicity were observed in those mice transduced with an HC-Ad vector as compared to an FG-Ad vector. The toxicity induced by FG-Ad vector gene delivery was dependent on mouse strain and vector dose. Animals treated with either HC-Ad and FG-Ad vectors developed non-neutralizing antibodies against Ad capsid and antibodies against βgal, but these antibodies did not cause loss of vector genomes from transduced muscle. In a mouse model of DMD, dystrophin gene transfer to muscle in utero using an HC-Ad vector restored the dystrophin-associated glycoproteins. Our results demonstrate that long-term transgene expression can be achieved by HC-Ad vector-mediated gene delivery to fetal muscle, although strategies of vector integration may need to be considered to accommodate muscle growth.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Gilchrist SC, Ontell MP, Kochanek S, Clemens PR . Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Mol Ther 2002; 6: 359–368.

    Article  CAS  Google Scholar 

  2. Mitchell M et al. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Therapy 2000; 7: 1986–1992.

    Article  CAS  Google Scholar 

  3. Turkay A, Saunders T, Kurachi K . Intrauterine gene transfer: gestational stage-specific gene delivery in mice. Gene Therapy 1999; 6: 1685–1694.

    Article  CAS  Google Scholar 

  4. Jerebtsova M, Batshaw ML, Ye X . Humoral immune response to recombinant adenovirus and adeno-associated virus after in utero administration of viral vectors in mice. Pediatr Res 2002; 52: 95–104.

    Article  CAS  Google Scholar 

  5. Lipshutz GS, Flebbe-Rehwaldt L, Gaensler KM . Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. Mol Ther 2000; 2: 374–380.

    Article  CAS  Google Scholar 

  6. Lipshutz GS et al. In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol Ther 2001; 3: 284–292.

    Article  CAS  Google Scholar 

  7. Schachtner S, Buck C, Bergelson J, Baldwin H . Temporally regulated expression patterns following in utero adenovirus-mediated gene transfer. Gene Therapy 1999; 6: 1249–1257.

    Article  CAS  Google Scholar 

  8. Schneider H et al. Sustained delivery of therapeutic concentrations of human clotting factor IX – a comparison of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4: 46–53.

    Article  Google Scholar 

  9. Yang EY et al. Persistent postnatal transgene expression in both muscle and liver after fetal injection of recombinant adenovirus. J Pediatr Surg 1999; 34: 766–772.

    Article  CAS  Google Scholar 

  10. Waddington SN et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood 2003; 101: 1359–1366.

    Article  CAS  Google Scholar 

  11. Bilbao R et al. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors. Gene Therapy 2003; 10: 1821–1829.

    Article  CAS  Google Scholar 

  12. Kochanek S . High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999; 10: 2451–2459.

    Article  CAS  Google Scholar 

  13. Jiang Z et al. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle. Gene Therapy 2004; 11: 1453–1461.

    Article  CAS  Google Scholar 

  14. Chen HH et al. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999; 10: 365–373.

    Article  Google Scholar 

  15. Camargo FD et al. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors. Mol Ther 2000; 2: 496–504.

    Article  CAS  Google Scholar 

  16. O'Hara AJ et al. The spread of transgene expression at the site of gene construct injection. Muscle Nerve 2001; 24: 488–495.

    Article  CAS  Google Scholar 

  17. Pegoraro E et al. Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 1995; 45: 677–690.

    Article  CAS  Google Scholar 

  18. Biermann V et al. Targeting of high-capacity adenoviral vectors. Hum Gene Ther 2001; 12: 1757–1769.

    Article  CAS  Google Scholar 

  19. Wills KN et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5: 1079–1088.

    Article  CAS  Google Scholar 

  20. Parks RJ et al. A helper-dependent adenoviurs vector system-removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565–13570.

    Article  CAS  Google Scholar 

  21. Bilbao R et al. Binding of adenoviral fiber knob to the coxsackievirus-adenovirus receptor is crucial for transduction of fetal muscle. Hum Gene Ther 2003; 14: 645–649.

    Article  CAS  Google Scholar 

  22. Bouri K et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999; 10: 1633–1640.

    Article  CAS  Google Scholar 

  23. MacKenzie TC et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6: 349–358.

    Article  CAS  Google Scholar 

  24. Anderson RD et al. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Therapy 2000; 7: 1034–1038.

    Article  CAS  Google Scholar 

  25. Jiang ZL et al. Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Mol Ther 2001; 3: 892–900.

    Article  CAS  Google Scholar 

  26. Lu QL, Partridge TA . A new blocking method for application of murine monoclonal antibody to mouse tissue sections. J Histochem Cytochem 1998; 46: 977–984.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank David Fink and Marina Mata (University of Pittsburgh, Pittsburgh, PA) for their contributions. We thank Merck & Co. Inc. for the helper virus AdLC8cluc and 293Cre4 cells that were used to grow AdmDys. This work was supported by NIH Grant P01 AR45925 (PRC), Muscular Dystrophy Association grants (PRC), and a postdoctoral fellowship grant from the Fundación Ramón Areces (RB).

Author information

Author notes

  1. R Bilbao and D P Reay: These authors contributed equally to this work

Authors and Affiliations

  1. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

    R Bilbao, D P Reay, E Wu, H Zheng & P R Clemens

  2. Center for Molecular Medicine, University of Cologne, Cologne, Germany

    V Biermann & S Kochanek

  3. Division of Gene Therapy, University of Ulm, Ulm, Germany

    S Kochanek

  4. Neurology Service, Department of Veterans Affairs Medical Center, Pittsburgh, PA, USA

    P R Clemens

Authors
  1. R Bilbao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D P Reay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Biermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Kochanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P R Clemens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bilbao, R., Reay, D., Wu, E. et al. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. Gene Ther 12, 39–47 (2005). https://doi.org/10.1038/sj.gt.3302392

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302392

Keywords

This article is cited by

Search

Advanced search

Quick links